Sydnexis

Closing the Critical Innovation Gap in Pediatric Progressive Myopia

United States · Founded 2014 · $45.0M raised

Employees
11–50
Founded
2014
Business Model
B2B
Total Funding
$45.0M
Last Round
$45.0M Series BAug 2021
Rounds
1

About

Sydnexis is a biopharmaceutical company dedicated to advancing care for pediatric progressive myopia, a degenerative condition that demands early, targeted intervention. Founded in 2014 and based in San Diego, the company is developing SYD-101, a proprietary low-dose atropine formulation engineered for growing eyes and evaluated in the Phase 3 STAR trial. Sydnexis aims to slow myopia progression at an early age and reduce the risk of irreversible long-term vision complications, addressing a critical innovation gap in pediatric ophthalmology.

Summary

Sydnexis is a Biotech company based in United States, founded in 2014. It has raised $45.0M in total across 1 round, most recently a $45.0M Series B round in Aug 2021.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BAug 2021
$45.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Sydnexis on Indexed.vc
<a href="https://indexed.vc/companies/sydnexis"><img src="https://indexed.vc/api/badge/company/sydnexis" alt="Sydnexis on Indexed.vc" width="260" height="76" /></a>